Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048099 | 1.00 | SIGMAR1 (0.42) | SIGMAR1HTR1AHTR7SLC6A2SLC6A4 | |
| SCHEMBL27755643 | 0.82 | BCHE (0.44) | SIGMAR1HTR1ASLC6A2SLC6A3 | |
| SCHEMBL4135403 | 0.81 | LTA4H (0.51) | SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4135394 | 0.81 | LTA4H (0.51) | SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9020873 | 0.79 | SIGMAR1 (0.59) | SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27735185 | 0.77 | ALDH1A1 (0.36) | — | |
| SCHEMBL3887187 | 0.76 | HRH3 (0.54) | SIGMAR1 | |
| Methyl Alcohol SCHEMBL27735067 | 0.76 | HRH3 (0.51) | SIGMAR1 | |
| SCHEMBL3897250 | 0.76 | MEN1 (0.40) | HTR1AHTR7 | |
| SCHEMBL13960252 | 0.76 | KCNA3 (0.65) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126969-B2 | Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2009-08-06 | — | — | US | disclosed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-2013197-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | SIGMAR1 1619/4885HTR1A 66/4885HTR7 136/4885 |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | RB1, CCNI, CDK2 | SIGMAR1 1743/4885HTR1A 2744/4885HTR7 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.